Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Honeywell Aerospace Inc.HONA · Entity 1656 | Director | August 03, 2026 | August 05, 2026 |
| METLIFE INCMET · Entity 488 | Director | October 01, 2026 | October 05, 2026 |
| MSCI Inc.MSCI · Entity 3075 | Director | May 01, 2026 | May 05, 2026 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Honeywell Aerospace Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 572 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 572 · Balance 572 F1: Instrument converts to Issuer's Common Stock on a one-for-one basis. F2: The Restricted Stock Units shall vest on April 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Instrument converts to Issuer's Common Stock on a one-for-one basis.
F2: The Restricted Stock Units shall vest on April 15, 2027.
METLIFE INC
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,125 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 544 · Balance 2,125 F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock.
MSCI Inc.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,059 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 388 · Balance 1,059 F1: Restricted stock units vesting on May 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units vesting on May 1, 2027.
Sana Biotechnology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-03 | Direct | 90,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 90,000 · Balance 90,000 F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:04 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 544 | $0.00 | $0.00 |
DisclosureSEC source: 0001836301-26-000020 · wk-form4_1791230684.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,125 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 23:35 UTC | Honeywell Aerospace Inc. HONA · Entity 1656 | GrantRestricted Stock Units · Derivative | 572 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-053683 · wk-form4_1785972946.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572 Underlying: Common Stock · 572 shares Expires not disclosed F1 · derivative.exercise_price: Instrument converts to Issuer's Common Stock on a one-for-one basis. F2 · derivative.exercise_date: The Restricted Stock Units shall vest on April 15, 2027. F2 · derivative.expiration_date: The Restricted Stock Units shall vest on April 15, 2027. Read SEC document |
| June 29, 2026 Filed Jul 2, 2026 00:29 UTC | Honeywell Aerospace Inc. HONA · Entity 1656 | GrantDeferred Compensation (Phantom Shares) · Derivative | 135.1441 | $226.24 | $30,575.00 |
DisclosureSEC source: 0001628280-26-046678 · wk-form4_1782952155.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135.1441 Underlying: Common Stock · 135.1441 shares Expires not disclosed F1 · derivative.exercise_price: Deferred Compensation (Phantom Shares) are allocated based on the price of common stock, par value $0.01 per share ("HONA Common Stock"), of Honeywell Aerospace Inc., a Delaware corporation ("HONA") on the contribution date by dividing the dollar amount of the contribution by the price per share of HONA Common Stock. HONA Common Stock prices are based on the mean of the highest and lowest sales price on the date of contribution. Phantom Shares are settled in cash based on the price of HONA Common Stock at settlement. F2 · derivative.exercise_date: Phantom shares are accrued under the Deferred Compensation Plan for Non-Employee Directors and will be settled in cash based on elections by the Reporting Person as permitted under the Plan. F2 · derivative.expiration_date: Phantom shares are accrued under the Deferred Compensation Plan for Non-Employee Directors and will be settled in cash based on elections by the Reporting Person as permitted under the Plan. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:11 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 587 | $0.00 | $0.00 |
DisclosureSEC source: 0001836301-26-000016 · wk-form4_1781813514.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,581 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:39 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001836301-26-000014 · primarydocument.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:05 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001836301-26-000012 · wk-form4_1778011531.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,059 F1 · shares: Restricted stock units vesting on May 1, 2027. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 721 | $0.00 | $0.00 |
DisclosureSEC source: 0001836301-26-000009 · wk-form4_1775246728.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 994 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:36 UTC | METLIFE INC MET · Entity 488 | GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001836301-26-000006 · wk-form4_1772141793.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273 F1 · kind: MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:39 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-004641 · primarydocument.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:05 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 385 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-25-000142 · wk-form4_1746475503.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 671 F1 · shares: Restricted stock units vesting on May 1, 2026. Read SEC document |
| August 05, 2024 Filed Aug 7, 2024 20:07 UTC | MSCI Inc. MSCI · Entity 3075 | GrantCommon Stock | 286 | $0.00 | $0.00 |
DisclosureSEC source: 0001408198-24-000145 · wk-form4_1723061264.xml · nonDerivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286 F1 · shares: Restricted stock units vesting on May 1, 2025. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:22 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 54,278 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-004842 · primarydocument.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,278 Underlying: Common Stock · 54,278 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. Read SEC document |
| June 06, 2024 Filed Jul 15, 2024 20:12 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001562180-24-005720 · primarydocument.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2034-06-05 F1 · shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:34 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005029 · primarydocument.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:37 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001562180-22-004944 · primarydocument.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 22:15 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005069 · doc4.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-02 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. Read SEC document |
| February 03, 2021 Filed Feb 18, 2021 23:54 UTC Amendment | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 11,795 | $0.00 Strike: $25.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007184 · doc4a.xml · derivative · entry 1 Seitz Michelle · CIK 0001836301 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,795 Underlying: Common Stock · 11,795 shares Expires 2031-02-02 F1 · shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F2 · derivative.exercise_date: The stock option shall vest and become exercisable in full on February 3, 2022. F1 · derivative.underlying_shares: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. F1 · balance_after: This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.